IP Verse

Exendin For Treating Diabetes And Reducing Body Weight - EP2347762B1

PatentPatent Analysis

EP2347762

AMYLIN PHARMACEUTICALS
Application Number
EP10016112A
Filing Date
Aug 18, 2006
Status
Revoked
Dec 15, 2023
Grant Date
May 8, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2341905B2

Bibliography

The patent EP2347762B1 was granted to Amylin Pharmaceuticals on May 8, 2019 following the initial filing on Aug 18, 2006 under the application number EP10016112A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 7, 2020ADMISSIBLE
INSTONEJan 21, 2020ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents